← Oncology Approval Tracker

FDA DECISION ·

Darzalex Faspro + Kyprolis + dexamethasone

daratumumab and hyaluronidase-fihj with carfilzomib and dexamethasone · Janssen Biotech / Amgen

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after one to three prior treatment lines.

LAMPGEN ANALYSIS

Why it matters

The regimen pairs subcutaneous daratumumab with carfilzomib and dexamethasone in previously treated myeloma.

What research teams should watch

Document the carfilzomib schedule and daratumumab route and track cardiac and infusion-related events across the combination.

PRIMARY RECORDS

Sources